TY - JOUR
T1 - Andexanet
T2 - Effectively reversing anticoagulation
AU - Lippi, Giuseppe
AU - Sanchis-Gomar, Fabian
AU - Favaloro, Emmanuel J
N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.
PY - 2016/6
Y1 - 2016/6
N2 - Despite direct oral anticoagulants becoming a mainstay of anticoagulant therapy, the effective, timely, and safe reversal of their anticoagulant effect remains challenging. Emerging evidence attests that andexanet, a recombinant and inactive variant of native factor X (FXa), competitively inhibits and counteracts the anticoagulant effect of many inhibitors of native activated FXa.
AB - Despite direct oral anticoagulants becoming a mainstay of anticoagulant therapy, the effective, timely, and safe reversal of their anticoagulant effect remains challenging. Emerging evidence attests that andexanet, a recombinant and inactive variant of native factor X (FXa), competitively inhibits and counteracts the anticoagulant effect of many inhibitors of native activated FXa.
KW - Administration, Oral
KW - Anticoagulants/adverse effects
KW - Antidotes/pharmacology
KW - Blood Coagulation/drug effects
KW - Factor Xa/pharmacology
KW - Humans
KW - Recombinant Proteins/pharmacology
U2 - 10.1016/j.tips.2016.03.002
DO - 10.1016/j.tips.2016.03.002
M3 - Review article
C2 - 27048885
SN - 0165-6147
VL - 37
SP - 413
EP - 414
JO - Trends in Pharmacological Sciences
JF - Trends in Pharmacological Sciences
IS - 6
ER -